

**MTN 037 - A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel)
Administered Rectally to HIV-1 Seronegative Adults
Report Generation Date: December 6, 2022
Visit Cutoff Date: November 29, 2022¹
Retention by Visit and Site**

	Pittsburgh	Birmingham	All Sites
Participants Enrolled	6	7	13
V3 Study Product Admin			
Expected ²	6	7	13
Completed ³	6 (100%)	7 (100%)	13 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
V4 24 Hour Post-Dose			
Expected ²	6	7	13
Completed ³	6 (100%)	7 (100%)	13 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
V4a 48 Hour Post-Dose			
Expected ²	2	2	4
Completed ³	2 (100%)	2 (100%)	4 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	4	5	9

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 037 - A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel)
Administered Rectally to HIV-1 Seronegative Adults
Report Generation Date: December 6, 2022
Visit Cutoff Date: November 29, 2022¹
Retention by Visit and Site**

	Pittsburgh	Birmingham	All Sites
V5 Study Product Admin			
Expected ²	6	7	13
Completed ³	6 (100%)	6 (86%)	12 (92%)
Not Completed	0 (0%)	1 (14%)	1 (8%)
Missed	0 (0%)	1 (14%)	1 (8%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
V6 24 Hour post-dose			
Expected ²	6	7	13
Completed ³	6 (100%)	6 (86%)	12 (92%)
Not Completed	0 (0%)	1 (14%)	1 (8%)
Missed	0 (0%)	1 (14%)	1 (8%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
V6a 48 Hour post-dose			
Expected ²	2	3	5
Completed ³	2 (100%)	2 (67%)	4 (80%)
Not Completed	0 (0%)	1 (33%)	1 (20%)
Missed	0 (0%)	1 (33%)	1 (20%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	4	4	8

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 037 - A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel)
Administered Rectally to HIV-1 Seronegative Adults
Report Generation Date: December 6, 2022
Visit Cutoff Date: November 29, 2022¹
Retention by Visit and Site**

	Pittsburgh	Birmingham	All Sites
V7 Study Product Admin			
Expected ²	6	7	13
Completed ³	6 (100%)	6 (86%)	12 (92%)
Not Completed	0 (0%)	1 (14%)	1 (8%)
Missed	0 (0%)	1 (14%)	1 (8%)
Terminated Early	0 (0%)	1 (14%)	1 (8%)
Not Expected	0	0	0
V8 24 Hour post-dose			
Expected ²	6	7	13
Completed ³	6 (100%)	5 (71%)	11 (85%)
Not Completed	0 (0%)	2 (29%)	2 (15%)
Missed	0 (0%)	2 (29%)	2 (15%)
Terminated Early	0 (0%)	1 (14%)	1 (8%)
Not Expected	0	0	0
V8a 48 Hour post-dose			
Expected ²	2	2	4
Completed ³	2 (100%)	2 (100%)	4 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	4	5	9

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 037 - A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel)
Administered Rectally to HIV-1 Seronegative Adults
Report Generation Date: December 6, 2022
Visit Cutoff Date: November 29, 2022¹
Retention by Visit and Site**

	Pittsburgh	Birmingham	All Sites
Final Contact			
Expected ²	6	7	13
Completed ³	6 (100%)	6 (86%)	12 (92%)
Not Completed			
Missed	0 (0%)	1 (14%)	1 (8%)
Terminated Early	0 (0%)	1 (14%)	1 (8%)
Not Expected	0	0	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.